A detailed history of Goldman Sachs Group Inc transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 80,556 shares of VRCA stock, worth $640,420. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,556
Holding current value
$640,420
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.95 - $7.95 $640,420 - $640,420
80,556 New
80,556 $640,000
Q1 2024

May 15, 2024

BUY
$4.74 - $6.81 $92,690 - $133,169
19,555 New
19,555 $115,000
Q3 2023

May 14, 2024

BUY
$3.75 - $7.46 $51,963 - $103,373
13,857 New
13,857 $53,000
Q3 2023

Nov 14, 2023

SELL
$3.75 - $7.46 $29,017 - $57,725
-7,738 Reduced 35.83%
13,857 $53,000
Q2 2023

May 14, 2024

SELL
$5.32 - $6.79 $258,392 - $329,790
-48,570 Reduced 69.22%
21,595 $124,000
Q2 2023

Aug 14, 2023

SELL
$5.32 - $6.79 $258,392 - $329,790
-48,570 Reduced 69.22%
21,595 $124,000
Q1 2023

May 14, 2024

BUY
$2.88 - $8.51 $151,404 - $447,379
52,571 Added 298.8%
70,165 $456,000
Q1 2023

May 11, 2023

BUY
$2.88 - $8.51 $202,075 - $597,104
70,165 New
70,165 $456,000
Q3 2022

May 14, 2024

SELL
$2.17 - $4.3 $30,718 - $60,870
-14,156 Reduced 44.59%
17,594 $51,000
Q3 2022

Nov 10, 2022

SELL
$2.17 - $4.3 $30,718 - $60,870
-14,156 Reduced 44.59%
17,594 $0
Q2 2022

May 14, 2024

BUY
$1.81 - $8.93 $57,467 - $283,527
31,750 New
31,750 $61,000
Q2 2022

Aug 15, 2022

BUY
$1.81 - $8.93 $37,915 - $187,065
20,948 Added 193.93%
31,750 $61,000
Q1 2022

May 16, 2022

BUY
$7.59 - $9.49 $81,987 - $102,510
10,802 New
10,802 $88,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.